Dr Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside.
Co-founder of ProlX Pharmaceuticals, Dr Kirkpatrick was CEO from 1999 until its acquisition by Biomira in 2006. From 2006 through 2008 she was chief scientific officer of the merged company, which changed its name to Oncothyreon in 2007.
Bob Gower, chairman of Ensysce, said: “Dr Kirkpatrick is a tremendous addition to our company. Lynn brings a vast array of skills that will help move Ensysce technology rapidly forward building value in the company and moving new technologies to the forefront of cancer treatment.”